Telix Pharmaceuticals Limited Stock Today
| TLPPF Stock | USD 16.00 0.82 5.40% |
Performance12 of 100
| Odds Of DistressOver 55
|
Telix Pharmaceuticals is trading at 16.00 as of the 15th of December 2024. This is a 5.40 percent increase since the beginning of the trading day. The stock's lowest day price was 16.0. Telix Pharmaceuticals has over 55 % chance of experiencing financial distress in the next 2 years of operation, but had a somewhat good returns during the last 90 days. The performance scores are derived for the period starting the 16th of September 2024 and ending today, the 15th of December 2024. Click here to learn more.
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company was founded in 2015 and is headquartered in North Melbourne, Australia. The company has 317.02 M outstanding shares. More on Telix Pharmaceuticals Limited
Moving against Telix Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Telix Pink Sheet Highlights
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Telix Pharmaceuticals Limited [TLPPF] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.44 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Telix Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Telix Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Telix Pharmaceuticals classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 317.02 M outstanding shares.
Telix Pharmaceuticals Limited has accumulated about 122.61 M in cash with (59.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.39.
Check Telix Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationTelix Pharmaceuticals shows a total of 317.02 Million outstanding shares. Telix Pharmaceuticals maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Telix Ownership Details
Telix Pharmaceuticals Risk Profiles
| Mean Deviation | 2.82 | |||
| Semi Deviation | 2.93 | |||
| Standard Deviation | 3.44 | |||
| Variance | 11.83 |
Telix Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Telix Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Content Syndication Now
Content SyndicationQuickly integrate customizable finance content to your own investment portal |
| All Next | Launch Module |
Telix Pharmaceuticals Corporate Management
| Jyoti BappSc | Chief APAC | Profile | |
| Meredith Crowe | Interim Culture | Profile | |
| BSc BSc | Chief Scientist | Profile | |
| Christian Davis | EMEA Marketing | Profile | |
| Andreas MD | Chief Director | Profile | |
| Amanda Griffin | Communications Mang | Profile | |
| BEng DPhil | Group CoFounder | Profile |
Additional Information and Resources on Investing in Telix Pink Sheet
When determining whether Telix Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Telix Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Telix Pharmaceuticals Limited Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Telix Pharmaceuticals Limited Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telix Pharmaceuticals Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.